Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
18.64
Dollar change
+0.05
Percentage change
0.27
%
IndexRUT P/E- EPS (ttm)-15.34 Insider Own28.39% Shs Outstand25.53M Perf Week18.58%
Market Cap475.88M Forward P/E- EPS next Y-2.40 Insider Trans16.61% Shs Float18.28M Perf Month17.31%
Income-124.65M PEG- EPS next Q-0.47 Inst Own58.87% Short Float2.59% Perf Quarter26.08%
Sales0.00M P/S- EPS this Y65.77% Inst Trans-2.70% Short Ratio3.55 Perf Half Y62.33%
Book/sh22.15 P/B0.84 EPS next Y14.35% ROA-48.85% Short Interest0.47M Perf Year32.25%
Cash/sh7.28 P/C2.56 EPS next 5Y25.90% ROE-51.95% 52W Range9.91 - 24.59 Perf YTD44.36%
Dividend Est.- P/FCF- EPS past 5Y-483.52% ROI-67.87% 52W High-24.20% Beta0.52
Dividend TTM- Quick Ratio39.20 Sales past 5Y0.00% Gross Margin- 52W Low88.17% ATR (14)1.20
Dividend Ex-DateMar 15, 2024 Current Ratio39.20 EPS Y/Y TTM-17.72% Oper. Margin0.00% RSI (14)61.32 Volatility7.52% 5.97%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price33.25
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q10.50% Payout- Rel Volume1.42 Prev Close18.59
Sales Surprise- EPS Surprise-330.49% Sales Q/Q- EarningsMay 08 AMC Avg Volume133.23K Price18.64
SMA2015.47% SMA501.76% SMA20033.22% Trades Volume189,518 Change0.27%
Date Action Analyst Rating Change Price Target Change
Apr-15-24Initiated William Blair Outperform
Apr-15-24Initiated Leerink Partners Outperform $32
Apr-10-24Initiated Citigroup Buy $34
Mar-27-24Initiated Piper Sandler Overweight $28
Feb-23-23Downgrade Cowen Outperform → Market Perform
Feb-23-23Downgrade Cantor Fitzgerald Overweight → Neutral $3
Feb-23-23Downgrade BofA Securities Neutral → Underperform $3 → $2
Jan-25-23Downgrade BTIG Research Buy → Neutral
Jan-18-23Downgrade BofA Securities Buy → Neutral $7 → $3
Jan-06-23Downgrade SVB Leerink Outperform → Mkt Perform $11 → $2
May-12-24 09:03AM
May-08-24 04:01PM
May-01-24 04:01PM
Apr-03-24 07:00AM
Apr-02-24 04:01PM
04:30PM Loading…
Mar-21-24 04:30PM
10:09AM
Mar-08-24 05:00PM
Mar-01-24 10:48AM
Feb-02-24 11:58AM
Jan-27-24 12:07PM
Nov-16-23 12:00PM
Nov-15-23 07:00AM
Jun-23-23 07:00AM
May-15-23 07:44AM
10:18AM Loading…
May-10-23 10:18AM
Apr-26-23 02:10PM
Mar-29-23 04:20PM
Mar-25-23 10:12AM
Mar-20-23 04:05PM
Feb-23-23 05:36PM
Feb-22-23 04:05PM
Jan-10-23 09:35AM
Jan-06-23 05:54PM
09:07AM
Jan-05-23 05:57PM
04:05PM
Dec-11-22 10:00AM
Nov-21-22 08:00AM
Nov-17-22 09:45AM
04:05PM Loading…
Nov-09-22 04:05PM
Nov-03-22 09:05AM
Oct-16-22 08:33AM
Oct-11-22 08:00AM
Sep-06-22 08:00AM
Aug-30-22 05:47PM
Aug-11-22 04:05PM
08:16AM
Jun-17-22 02:26PM
Jun-01-22 08:00AM
May-29-22 02:15PM
May-16-22 06:00AM
May-12-22 04:05PM
May-09-22 08:13AM
May-04-22 08:00AM
May-03-22 08:00AM
May-02-22 04:38PM
Mar-28-22 08:00AM
Mar-23-22 12:28PM
08:00AM
Mar-21-22 08:25AM
Mar-03-22 08:00AM
Mar-02-22 08:00AM
Feb-08-22 10:20AM
Jan-27-22 08:00AM
Jan-26-22 06:30PM
Dec-11-21 09:00AM
Dec-07-21 08:00AM
Nov-17-21 08:00AM
Nov-10-21 04:05PM
Nov-04-21 09:13AM
Oct-21-21 08:00AM
Oct-18-21 11:00AM
04:37AM
Oct-12-21 01:00PM
Oct-05-21 08:00AM
Sep-25-21 10:12AM
Aug-30-21 08:00AM
Aug-12-21 04:05PM
Jun-30-21 05:15PM
Jun-24-21 09:08PM
LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Del Mar, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chevallard Daniel R.Chief Financial OfficerMay 14 '24Buy15.683,18849,9883,188May 15 04:13 PM
MCCOLLUM JAMES WDirectorMay 13 '24Buy15.9931,332501,093525,565May 14 05:29 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 21 '24Buy15.03998,00915,000,0753,319,339Mar 25 08:48 PM